Loading...
•
Dec 31, 2024
AbCellera Q4 2024 Earnings Report
AbCellera reported fourth quarter results, highlighting revenue and net loss figures.
Key Takeaways
AbCellera reported Q4 2024 revenue of $5.1 million and a net loss of $34.2 million. The company continues to advance its pipeline and invest in its capabilities.
Revenue for Q4 2024 was $5.1 million, primarily from research fees.
Operating expenses for Q4 2024 totaled $77.8 million, including investments in co-development and internal programs.
Net loss for Q4 2024 was $34.2 million, or $(0.12) per share.
Abdera advanced ABD-147 into a Phase 1 clinical trial.
Revenue by Segment
Forward Guidance
AbCellera is on track to initiate Phase 1 clinical trials for ABCL635 and ABCL575 and start activities in its new clinical manufacturing facility in 2025.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...